SAGE) traded lower for the third straight session on Tuesday after Bank of America moved the stock’s rating to Underperform, ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

Biogen's $3 billion alliance with Sage Therapeutics has suffered another setback after their drug for essential tremor failed to move the needle in a phase 2 study. Topline results from the ...

The reimbursement from Biogen to Sage for R&D expenses pursuant to the Sage/Biogen Collaboration and License Agreement was $0.2 million in the first quarter of 2025 compared to $5.7 million in the ...

Speaking of Sage, news broke recently of an unsolicited buyout offer of $7.22 a share from Biogen that was rejected. To my mind, this speaks to the promise they see in this drug and the team at ...

Sales are likely to have improved sequentially in the first quarter. Biogen has a collaboration with Sage Therapeutics SAGE for Zurzuvae. Biogen and Sage equally share profits and losses for the ...

SAGE markets its new depression drug Zurzuvae (zuranolone) in partnership with drug giant Biogen BIIB. Zurzuvae, the first and only oral treatment indicated for adults with postpartum depression ...

January 27, 2025 Sage rejects Biogen's $469 million takeover offer, says offer undervalues company Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million ...

Sage Therapeutics, Inc. SAGE reported a loss of $1.01 per share for the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 99 cents. The company had reported a loss of $1. ...